# US 2026/0242329 A1 · An improved process for the preparation of intermediates used in the preparation of dasatinib

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0242329 A1
- Document ID: US20260242329A1
- Status: Published application
- Kind: A1
- Application number: 19/164,910
- Filed: 2024-03-12
- Published: 2026-08-20
- Earliest claimed: 2023-03-16
- Assignees: Ocimum Labs Private Limited
- Applicants: Ocimum Labs Private Limited
- Inventors: Harikrishna Mudduluru; Munisekhar Reddy Sannareddy; Salivahanaiah Akkili; Mahender Reddy Marri
- Web page: https://patentgrep.com/patent/US20260242329A1

## CPC

- C07C 209/62: by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds (C07C209/24 takes precedence)
- C07C 209/68: from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
- C07C 303/22: from sulfonic acids, by reactions not involving the formation of sulfo or halosulfonyl groups; {from sulfonic halides by reactions not involving the formation of halosulfonyl groups}
- C07D 417/12: linked by a chain containing hetero atoms as chain links
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to an improved process for the preparation of intermediate compounds used in the preparation of Dasatinib. The present invention specifically relates to an improved process for the preparation of intermediate compound of Formula (I) used in the preparation of Dasatinib or its pharmaceutically acceptable salts.

## Claims

### Claim at position 1

1: An improved process for the preparation of intermediate compound of Formula (I)
which comprises:
a) providing the sodium salt of 4-acetamido-3-methyl benzenesulphonate compound of Formula (II)
and reacting with chlorinating agent, and oxone in the presence or absence of a polar solvent to obtain an intermediate compound of Formula (III),
b) hydrolysing the acyl group of intermediate compound of Formula (I) using an acid to produce the intermediate compound of Formula (IV),
c) desulphonation of intermediate compound of Formula (IV) using an acid in solvent and extraction of the product using a solvent to produce the intermediate compound of Formula (I).

### Claim at position 2

2: An improved process for the preparation of intermediate compound of Formula (I)
which comprises:
a) providing the sodium salt of 4-acetamido-3-methyl benzenesulphonate compound of Formula (II)
and reacting with chlorinating agent, concentrated hydrochloric acid and Oxone® to obtain an intermediate compound of Formula (III),
b) hydrolysing the acyl group of intermediate compound of Formula (I) using concentrated hydrochloric acid to produce the intermediate compound of Formula (IV),
c) desulphonation of intermediate compound of Formula (IV) using concentrated hydrochloric acid in sulfolane solvent and extraction of the product in dichloromethane to produce the intermediate compound of Formula (I).

### Claim at position 3 (depends on 1)

3: The process as claimed in claim 1, wherein the intermediate compound of formula (I) is utilised in the preparation of Dasatinib or its pharmaceutically acceptable salts of Formula (V)

### Claim at position 4 (depends on 1)

4: The process as claimed in claim 1, wherein the chlorinating agent is HCl, NaCl, KCl, NH4Cl.

### Claim at position 5 (depends on 1)

5: The process as claimed in claim 1, wherein the solvent is methanol, ethanol, n-propanol, isopropanol, n-butano, t-butanol, benzene, toluene, xylene, heptane, hexane, acetone, ethyl methyl ketone, diethyl ketone, methyl tert-butyl ketone, isopropyl ketone, methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, n-butyl acetate, isobutyl acetate, sec-butyl acetate, acetonitrile, propionitrile, butyronitrile and isobutyronitrile, di-tert-butylether, dimethylether, diethylether, diisopropyl ether, 1,4-dioxane, methyltert-butylether, ethyl tert-butyl ether, tetrahydrofuran, 2-methyl tetrahydrofuran, 2-methoxyethanol, dimethoxyethane, formamide, DMF, DMAC, N-methyl-2-pyrrolidone, N-methylformamide, 2-pyrrolidone, 1-ethenyl-2-pyrrolidone, dichloromethane, 1,2-dichloroethane, chloroform, diethylenetriamine, ethylenediamine, morpholine, piperidine, pyridine, quinoline, tributylamine, diisopropyl amine, sulfolane and water.

### Claim at position 6 (depends on 5)

6: The solvent as claimed in claim 5, wherein the solvent is methanol, ethanol, n-propanol, isopropanol, n-butano, t-butanol, acetonitrile, propionitrile, butyronitrile, isobutyronitrile, dichloromethane, 1,2-dichloroethane, chloroform, sulfolane and water.

### Claim at position 7 (depends on 1)

7: The process as claimed in claim 1, wherein the hydrolysis is carried out using conc. HCl, H2SO4 and H3PO4.

### Claim at position 8 (depends on 1)

8: The process as claimed in claim 1, wherein the desulphonation is carried out using acid selected from HCl, H2SO4 and H3PO4.

### Claim at position 9 (depends on 2)

9: The process as claimed in claim 2, wherein the intermediate compound of formula (I) is utilised in the preparation of Dasatinib
or its pharmaceutically acceptable salts of Formula (V)
